GPC Biotech to Present at UBS Global Life Sciences Conference in New
York
Martinsried/Munich (Germany) and Princeton, N.J., September 20, 2007
- GPC Biotech AG (Frankfurt Stock Exchange: GPC; TecDAX index;
NASDAQ: GPCB) today announced that the Company will give a corporate
presentation at the upcoming UBS Global Life Sciences Conference in
New York, NY.
The presentation at the UBS conference will be on Wednesday,
September 26 at 9:00 AM ET/ 15:00 CET at the Grand Hyatt Hotel in New
York, NY.
The presentation will be webcast live and will be accessible through
the GPC Biotech Web site at www.gpc-biotech.com. A replay will also
be available via the Web site.
About GPC Biotech
GPC Biotech AG is a publicly traded biopharmaceutical company focused
on discovering, developing and commercializing new anticancer drugs.
GPC Biotech's lead product candidate satraplatin is currently in a
Phase 3 registrational trial in second-line hormone-refractory
prostate cancer. Satraplatin was in-licensed from Spectrum
Pharmaceuticals, Inc. GPC Biotech has ongoing various drug
development and discovery programs and also has an active program to
identify and pursue promising drug development in-licensing
opportunities. GPC Biotech AG is headquartered in Martinsried/Munich
(Germany) and has a wholly owned U.S. subsidiary headquartered in
Princeton, New Jersey. For additional information, please visit GPC
Biotech's Web site at www.gpc-biotech.com.
This press release contains forward-looking statements, which express
the current beliefs and expectations of the management of GPC Biotech
AG. Such statements are based on current expectations and are
subject to risks and uncertainties, many of which are beyond our
control, that could cause future results, performance or achievements
to differ significantly from the results, performance or achievements
expressed or implied by such forward-looking statements. Actual
results could differ materially depending on a number of factors, and
we caution investors not to place undue reliance on the
forward-looking statements contained in this press release. In
particular, there can be no guarantee that the results from the final
analysis of overall survival data from the SPARC trial will be
available when anticipated or sufficient to support regulatory
approval in the United States or elsewhere. In addition, there can
be no guarantee that additional information relating to the safety,
efficacy or tolerability of satraplatin will not be obtained upon
further analysis of data from the SPARC trial or analysis of
additional data from other ongoing clinical trials for satraplatin.
Furthermore, we cannot guarantee that satraplatin will be approved
for marketing in a timely manner, if at all, by regulatory
authorities nor that, if marketed, satraplatin will be a successful
commercial product. Additionally, we cannot guarantee that our
efforts to in-license drug development candidates will be successful
nor that, if we do in-license candidates, these programs will be
successfully developed and approved for marketing. We direct you to
GPC Biotech's Annual Report on Form 20-F for the fiscal year ended
December 31, 2006 and other reports filed with the U.S. Securities
and Exchange Commission for additional details on the important
factors that may affect the future results, performance and
achievements of GPC Biotech. Forward-looking statements speak only as
of the date on which they are made and GPC Biotech undertakes no
obligation to update these forward-looking statements, even if new
information becomes available in the future.
Satraplatin has not yet been approved by the FDA in the U.S., the
EMEA in Europe or any other regulatory authority and no conclusions
can or should be drawn regarding its safety or effectiveness. Only
the relevant regulatory authorities can determine whether satraplatin
is safe and effective for the use(s) being investigated.
Contacts:
GPC Biotech AG
Martin Braendle
Director, Investor Relations & Corporate Communications
Phone: +49 (0)89 8565-2693
ir@gpc-biotech.com
In the U.S.: Laurie Doyle
Director, Investor Relations & Corporate Communications
Phone: +1 609 524 5884
usinvestors@gpc-biotech.com
--- End of Message ---
GPC Biotech AG
Fraunhoferstr. 20 Martinsried
WKN: 585150; ISIN:
DE0005851505; Index: CDAX, MIDCAP, Prime All Share, TecDAX, HDAX,
TECH All Share;
Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in
Börse Berlin,
Freiverkehr in Bayerische Börse München, Freiverkehr in Börse
Düsseldorf,
Freiverkehr in Börse Stuttgart, Freiverkehr in Hanseatische
Wertpapierbörse zu Hamburg,
Geregelter Markt in Frankfurter Wertpapierbörse;